Michael Nakai

Michael Nakai

Auto-generated profile, based on publicly available information

Michael Nakai

Hypertension Research Laboratory, Victorian Heart Institute and Department of Pharmacology, Biomedical Discovery Institute, Faculty of Medicine, Nursing, and Health Sciences, Monash University, Melbourne, Australia (R.R.M., T.Z., E.D., L.X., A.B.-W., H.A.J., M.N., M.P., K.C.L., W.Q., J.A.O.D., F.Z.M.)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
ABAnna Beale
Anna Beale
JOJoanne A. O’donnell
Joanne A. O’donnell
MNMichael E. Nakai
Michael E. Nakai
SNShane Nanayakkara
Shane Nanayakkara
DVDonna Vizi
Donna Vizi
DKDavid Kaye
David Kaye
Background: Risk factors for heart failure with preserved ejection fraction (HFpEF) include hypertension, age, sex, and obesity. Emerging evidence suggests that the gut microbiota independently contributes to each one of these risk factors, potentially mediated via gut microbial‐derived metabolites such as short‐chain fatty acids. In this study, we determined whether the gut microbiota were associated with HFpEF and its risk factors. Methods and Results: We recruited 26 patients with HFpEF and 67 control participants from 2 independent communities. Patients with HFpEF were diagnosed by exercise right heart catheterization. We assessed the gut microbiome by bacterial 16S rRNA sequencing and food intake by the food frequency questionnaire. There was a significant difference in α‐diversity (eg, number of microbes) and β‐diversity (eg, type and abundance of microbes) between both cohorts of controls and patients with HFpEF ( P =0.001). We did not find an association between β‐diversity and specific demographic or hemodynamic parameters or risk factors for HFpEF. The Firmicutes to Bacteroidetes ratio, a commonly used marker of gut dysbiosis, was lower, but not significantly so ( P =0.093), in the patients with HFpEF. Compared with controls, the gut microbiome of patients with HFpEF was depleted of bacteria that are short‐chain fatty acid producers. Consistent with this, participants with HFpEF consumed less dietary fiber (17.6±7.7 versus 23.2±8.8 g/day; P =0.016). Conclusions: We demonstrate key changes in the gut microbiota in patients with HFpEF, including the depletion of bacteria that generate metabolites known to be important for cardiovascular homeostasis. Further studies are required to validate the role of these gut microbiota and metabolites in the pathophysiology of HFpEF.

9 January 2023 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
HJHamdi A. Jama
Hamdi A. Jama
DRDakota Rhys-Jones
Dakota Rhys-Jones
MNMichael Nakai
Michael Nakai
CYChu K. Yao
Chu K. Yao
RCRachel E. Climie
Rachel E. Climie
FMFrancine Z. Marques
Francine Z. Marques

14 February 2025 in Circulation Research
Verified
Journal Article
Closed access
RMRikeish R. Muralitharan
Rikeish R. Muralitharan
TZTenghao Zheng
Tenghao Zheng
EDEvany Dinakis
Evany Dinakis
LXLiang Xie
Liang Xie
ABAnastasia Barbaro-Wahl
Anastasia Barbaro-Wahl
FMFrancine Z. Marques
Francine Z. Marques
BACKGROUND: Fermentation of dietary fiber by the gut microbiota leads to the production of metabolites called short-chain fatty acids, which lower blood pressure and exert cardioprotective effects. Short-chain fatty acids activate host signaling responses via the functionally redundant receptors GPR41 (G-protein-coupled receptor 41) and GPR43 (G-protein-coupled receptor 43), which are highly expressed by immune cells. Whether and how these receptors protect against hypertension or mediate the cardioprotective effects of dietary fiber remains unknown. METHODS: Cardiovascular phenotype was assessed in untreated and Ang II (angiotensin II) treated hypertensive wild-type and GPR41/43 knockout (KO) double knockout male mice fed diets with different levels of fiber content. Some mice received TLR4 (toll-like receptor 4)-antagonist treatment and bone marrow chimeras. SNPs (single-nucleotide polymorphisms) associated with GPR41 and GPR43 expression were assessed in UK Biobank participants. RESULTS: Untreated GPR41/43KO mice had unaltered blood pressure but had greater cardiac and renal collagen deposition with higher macrophage numbers in the kidney compared with wild-type mice. Ang II–treated GPR41/43KO mice showed higher systolic blood pressure, cardiorenal weights and collagen deposition, and increased gut permeability, which allows the translocation of gastrointestinal bacterial components such as lipopolysaccharides into the circulation. The use of an antagonist to the lipopolysaccharide receptor, TLR4, a potent proinflammatory signaling molecule, restored the cardiovascular phenotype in GPR41/43KO mice. The lack of GPR41/43 expression in the immune compartment was sufficient to lead to a worsened hypertensive phenotype. We also demonstrate that GPR41/43 is, at least partially, responsible for the blood pressure–lowering and cardioprotective effects of a high-fiber diet. Finally, using the UK Biobank, we provide translational evidence that variants associated with lower expression of both GPR41 and GPR43 are more prevalent in participants with hypertension. CONCLUSIONS: Our findings highlight that lack of short-chain fatty acid-receptor signaling via both GPR41 and GPR43 increases risk of high blood pressure, suggesting treatments that target these receptors could be a novel strategy to prevent or treat hypertension.

1 August 2022 in Hypertension
Verified
Journal Article
Closed access
PDF file
EDEvany Dinakis
Evany Dinakis
MNMichael Nakai
Michael Nakai
PGPaul Gill
Paul Gill
RRRosilene Ribeiro
Rosilene Ribeiro
SYStephanie Yiallourou
Stephanie Yiallourou
FMFrancine Z. Marques
Francine Z. Marques
Background: Blood pressure (BP) variability is an independent risk factor for cardiovascular events. Recent evidence supports a role for the gut microbiota in BP regulation. However, whether the gut microbiome is associated with BP variability is yet to be determined. Here, we aimed to investigate the interplay between the gut microbiome and their metabolites in relation to BP variability. Methods: Ambulatory BP monitoring was performed in 69 participants from Australia (55.1% women; mean±SD, 59.8±7.26 years; body mass index, 25.2±2.83 kg/m 2 ). These data were used to determine nighttime dipping, morning BP surge (MBPS) and BP variability as SD. The gut microbiome was determined by 16S ribosomal RNA (rRNA) sequencing and metabolite levels by gas chromatography. Results: We identified specific taxa associated with systolic BP variability, nighttime dipping, and MBPS. Notably, Alistipesfinegoldii and Lactobacillus spp. were only present in participants within the normal ranges of BP variability, MBPS and dipping, while Prevotella spp. and Clostridium spp., were found to be present in extreme dippers and the highest quartiles of BP SD and MBPS. There was a negative association between MBPS and microbial α-diversity (r=−0.244, P =0.046). MBPS was also negatively associated with plasma levels of microbial metabolites called short-chain fatty acids (r=−0.305, P =0.020), particularly acetate (r=−0.311, P =0.017). Conclusions: Gut microbiome diversity, levels of microbial metabolites, and the bacteria Alistipesfinegoldii and Lactobacillus were associated with lower BP variability and Clostridium and Prevotella with higher BP variability. Thus, our findings suggest the gut microbiome and metabolites may be involved in the regulation of BP variability.

2 August 2024 in Circulation Research
Verified
Journal Article
Closed access
HJHamdi A. Jama
Hamdi A. Jama
MDMalathi S.I. Dona
Malathi S.I. Dona
EDEvany Dinakis
Evany Dinakis
MNMichael Nakai
Michael Nakai
MPMadeleine R. Paterson
Madeleine R. Paterson
FMFrancine Z. Marques
Francine Z. Marques

1 June 2021 in Hypertension
Verified
Journal Article
Closed access
PDF file
Matthew SnelsonMatthew Snelson
Matthew Snelson
RMRikeish R. Muralitharan
Rikeish R. Muralitharan
EDEvany Dinakis
Evany Dinakis
MNMichael Nakai
Michael Nakai
HJHamdi A. Jama
Hamdi A. Jama
FMFrancine Z. Marques
Francine Z. Marques